New brain filter aims to prevent strokes during heart procedure

NCT ID NCT06689839

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new device called the Encompass F2, which is designed to catch debris that might travel to the brain during a common heart valve replacement procedure (TAVR). The goal is to see if it reduces the risk of stroke and brain damage compared to standard care. About 500 patients with aortic stenosis will be randomly assigned to receive the F2 device or standard care, and their outcomes will be tracked.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
F2 Filter and Delivery System (a cerebral protection device)
What this could lead to
If it works, this device could lower the chance of stroke and brain injury during TAVR, making the procedure safer for patients with aortic stenosis.
What could go wrong
This is an early-stage device trial with no phase designation, so results may not confirm benefit. There is also a risk of complications from the device itself, such as vascular injury or device-related stroke.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Age ≥ 50 years. * Patient meets the established criteria and indications for commercially available TAVR via transfemoral access and is scheduled to undergo TAVR per their treating physician. * Patient is willing and able to comply with protocol-specified follow-up evaluations. * Patient is able and willing to provide written informed consent. * Patient meets all criteria for use of control device (Sentinel device, per IFU). Key Exclusion Criteria: General Exclusion Criteria: * Patient requires an urgent or emergent TAVR procedure. * Any interventional cardiovascular procedure performed within 30 days prior to TAVR procedure or planned within 30 days post-TAVR procedure. * Diagnostic cardiac catheterization within 10 days prior to TAVR procedure. * Evidence of an acute myocardial infarction within 3 months prior to TAVR procedure. * Prior prosthetic heart valve in any position. * Known intracardiac thrombus. * Active infection or endocarditis. * Patient is contraindicated for anti-platelet and/or anticoagulant therapy. * Patient refuses blood transfusion. * Renal insufficiency (creatinine \> 2.5 mg/dL or GFR \< 30) and/or renal replacement therapy at the time of screening. * Patients with hepatic failure (Child-Pugh class C). * Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) \< 30%. * Females who are pregnant or nursing or plan to become pregnant during their participation in the study. Neurological Exclusion Criteria: * Modified Rankin Scale (mRS) ≥ 2 at screening. * Cerebrovascular event including TIA within 6 months of the procedure. * Patient has active major psychiatric disease, known mental or physical illness or known history of substance abuse that may cause non-compliance with the protocol or confound the data interpretation. * Patient has severe visual, auditory, or learning impairment. * Patient has neurodegenerative or other progressive neurological disease or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities. Magnetic Resonance Imaging Exclusion Criteria: * Contraindications to MRI (participants with MR unsafe implants including implantable temporary or permanent pacemaker or defibrillator, metal implants in field of view, metallic fragments, clips, or devices in the brain or eye before TAVR procedure). * High risk of complete AV block after TAVR, with the need of permanent pacemaker. * Claustrophobia precluding MRI scanning. Anatomical and CT Exclusion Criteria: * Severe peripheral arterial, abdominal aortic, or thoracic aortic disease that precludes delivery sheath, vascular access or filter deployment. * Presence of cardiovascular implant in aorta and/or peripheral access vessels. * Access vessels with excessive tortuosity. * Aortic arch, which is heavily calcified, severely atheromatous, or severely tortuous.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aortic diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cleveland Clinic Foundation

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Cumc/Nyph

    RECRUITING

    New York, New York, 10032, United States

  • Henry Ford Hospital

    RECRUITING

    Detroit, Michigan, 48202, United States

  • Monash Health Public

    RECRUITING

    Clayton, Victoria, 3168, Australia

  • NCH Baker Hospital-Naples Heart Institute

    NOT_YET_RECRUITING

    Naples, Florida, 34102, United States

  • Ohio Health Research Institute (aka Riverside Methodist Hospital)

    NOT_YET_RECRUITING

    Columbus, Ohio, 43214, United States

  • St Andrews War Memorial Hospital

    NOT_YET_RECRUITING

    Spring Hill, Queensland, 4000, Australia

  • St. Lukes Hospital Of Kansas City

    RECRUITING

    Kansas City, Missouri, 64111, United States

  • St. Vincent Hospital

    RECRUITING

    Indianappolis, Indiana, 46260, United States

  • University of Virginia Medical Center

    NOT_YET_RECRUITING

    Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.